{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:12:59Z","timestamp":1791637979518,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This pooled subanalysis of five multicenter, prospective, open-label, single-arm studies on esaxerenone aimed to evaluate the efficacy, organ-protective effects, and safety of esaxerenone in hypertensive patients with type 2 diabetes mellitus (T2DM), with and without concomitant sodium\u2013glucose cotransporter-2 inhibitor (SGLT2i) therapy. In total, 283 and 279 patients were included in the safety (with SGLT2i, 148; without, 135) and full analysis sets (with SGLT2i; 145; without, 134), respectively. Significant changes in morning home systolic\/diastolic blood pressure (SBP\/DBP) from baseline to Week 12 were shown in the overall population (mean change: \u221211.9\/\u22125.2\u2009mmHg, both\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and both SGLT2i and non-SGLT2i subgroups (\u221211.3\/\u22124.8 and \u221212.5\/\u22125.7\u2009mmHg, respectively, all\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). Similar findings were observed in bedtime home and office SBP\/DBP. The proportions of patients who achieved target home SBP\/DBP\u2009&lt;\u2009135\/85\u2009mmHg were 71.2% (overall population) and 70.5% and 71.9% in the SGLT2i and non-SGLT2i subgroups, respectively. The urine albumin-to-creatinine ratio significantly improved from baseline to Week 12 in the overall population and SGLT2i subgroups (percentage change in geometric mean from baseline: \u221242.8%, \u221243.0%, and \u221242.6%, respectively, all\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). N-terminal pro-B-type natriuretic peptide levels improved in all groups. The incidence of serum potassium \u22655.5\u2009mEq\/L was 2.0% vs 5.2% in the SGLT2i vs non-SGLT2i subgroups. Esaxerenone demonstrated significant BP-lowering effects, and improved renal and cardiovascular parameters, regardless of SGLT2i use. Safety was consistent across groups, with the numerically lower incidence of serum potassium \u22655.5\u2009mEq\/L in the SGLT2i subgroup suggesting a potential mitigating effect of SGLT2is on the risk of hyperkalemia.\n                  <\/jats:p>","DOI":"10.1038\/s41440-025-02347-0","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T06:21:23Z","timestamp":1756707683000},"page":"2924-2937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of esaxerenone with and without sodium\u2013glucose cotransporter-2 inhibitor use in hypertensive patients with type 2 diabetes mellitus: a pooled analysis of five clinical studies"],"prefix":"10.1038","volume":"48","author":[{"given":"Hirohiko","family":"Motoki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kuwahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito A.","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuomi","family":"Kario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Shimosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Suedomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"2347_CR1","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1161\/CIRCRESAHA.118.313219","volume":"124","author":"K Kario","year":"2019","unstructured":"Kario K, Thijs L, Staessen JA. Blood pressure measurement and treatment decisions: masked and white coat hypertension. Circ Res. 2019;124:990\u20131008.","journal-title":"Circ Res"},{"key":"2347_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1001\/jamacardio.2018.1233","volume":"3","author":"T Fujiwara","year":"2018","unstructured":"Fujiwara T, Yano Y, Hoshide S, Kanegae H, Kario K. Association of cardiovascular outcomes with masked hypertension defined by home blood pressure monitoring in a Japanese General practice population. JAMA Cardiol. 2018;3:583\u201390.","journal-title":"JAMA Cardiol"},{"key":"2347_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1161\/HYPERTENSIONAHA.114.04262","volume":"64","author":"K Kario","year":"2014","unstructured":"Kario K, Saito I, Kushiro T, Teramukai S, Ishikawa Y, Mori Y, et al. Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study. Hypertension. 2014;64:989\u201396.","journal-title":"Hypertension"},{"key":"2347_CR4","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jacc.2016.01.037","volume":"67","author":"K Kario","year":"2016","unstructured":"Kario K, Saito I, Kushiro T, Teramukai S, Tomono Y, Okuda Y, et al. Morning home blood pressure is a strong predictor of coronary artery disease: the HONEST study. J Am Coll Cardiol. 2016;67:1519\u201327.","journal-title":"J Am Coll Cardiol"},{"key":"2347_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/HYPERTENSIONAHA.116.07201","volume":"68","author":"S Hoshide","year":"2016","unstructured":"Hoshide S, Yano Y, Haimoto H, Yamagiwa K, Uchiba K, Nagasaka S, et al. Morning and evening home blood pressure and risks of incident stroke and coronary artery disease in the Japanese general practice population: the Japan morning surge-home blood pressure study. Hypertension. 2016;68:54\u201361.","journal-title":"Hypertension"},{"key":"2347_CR6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1161\/HYPERTENSIONAHA.118.11388","volume":"72","author":"K Kario","year":"2018","unstructured":"Kario K, Iwashita M, Okuda Y, Sugiyama M, Saito I, Kushiro T, et al. Morning home blood pressure and cardiovascular events in Japanese hypertensive patients. Hypertension. 2018;72:854\u201361.","journal-title":"Hypertension"},{"key":"2347_CR7","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/s41440-021-00686-2","volume":"44","author":"K Narita","year":"2021","unstructured":"Narita K, Hoshide S, Kario K. Difference between morning and evening home blood pressure and cardiovascular events: the J-HOP Study (Japan Morning Surge-Home Blood Pressure). Hypertens Res. 2021;44:1597\u2013605.","journal-title":"Hypertens Res"},{"key":"2347_CR8","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41440-022-00860-0","volume":"45","author":"S Uchida","year":"2022","unstructured":"Uchida S, Kikuya M, Asayama K, Ohata C, Kimura T, Tatsumi Y, et al. Predictive power of home blood pressure in the evening compared with home blood pressure in the morning and office blood pressure before treatment and in the on-treatment follow-up period: a post hoc analysis of the HOMED-BP study. Hypertens Res. 2022;45:722\u20139.","journal-title":"Hypertens Res"},{"key":"2347_CR9","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41440-022-01136-3","volume":"46","author":"S Hata","year":"2023","unstructured":"Hata S, Ushigome E, Hosomi Y, Yoshimura T, Takegami M, Kitagawa N, et al. Impact of continued high blood pressure on the progression of diabetic nephropathy after 10 years: KAMOGAWA-HBP study. Hypertens Res. 2023;46:565\u201374.","journal-title":"Hypertens Res"},{"key":"2347_CR10","first-page":"575","volume":"34","author":"JR Petrie","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34:575\u201384.","journal-title":"Can J Cardiol"},{"key":"2347_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"MAB Khan","year":"2020","unstructured":"Khan MAB, Hashim MJ, King JK, et al. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10:107\u201311.","journal-title":"J Epidemiol Glob Health"},{"key":"2347_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.arr.2016.01.007","volume":"26","author":"TW Buford","year":"2016","unstructured":"Buford TW. Hypertension and aging. Ageing Res Rev. 2016;26:96\u2013111.","journal-title":"Ageing Res Rev"},{"key":"2347_CR13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"2347_CR14","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.2174\/1381612825666190306162658","volume":"24","author":"PA Sarafidis","year":"2018","unstructured":"Sarafidis PA, Memmos E, Alexandrou ME, Papagianni A. Mineralocorticoid receptor antagonists for nephroprotection: current evidence and future perspectives. Curr Pharm Des. 2018;24:5528\u201336.","journal-title":"Curr Pharm Des"},{"key":"2347_CR15","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","volume":"143","author":"G Filippatos","year":"2021","unstructured":"Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021;143:540\u201352.","journal-title":"Circulation"},{"key":"2347_CR16","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"2347_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13566","volume":"16","author":"X Xu","year":"2024","unstructured":"Xu X, Feng J, Cui Y, Li P, Dong J, Liao L. Renal effects and safety between Asian and non-Asian chronic kidney disease and type 2 diabetes treated with nonsteroidal mineralocorticoid antagonists. J Diabetes. 2024;16:e13566.","journal-title":"J Diabetes"},{"key":"2347_CR18","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"2347_CR19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharm. 2015;761:226\u201334.","journal-title":"Eur J Pharm"},{"key":"2347_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s13318-022-00760-1","volume":"47","author":"SM Jankovi\u0107","year":"2022","unstructured":"Jankovi\u0107 SM, Jankovi\u0107 SV. Clinical pharmacokinetics and pharmacodynamics of esaxerenone, a novel mineralocorticoid receptor antagonist: a review. Eur J Drug Metab Pharmacokinet. 2022;47:291\u2013308.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2347_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41440-020-00569-y","volume":"44","author":"H Rakugi","year":"2021","unstructured":"Rakugi H, Yamakawa S, Sugimoto K. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone. Hypertens Res. 2021;44:371\u201385.","journal-title":"Hypertens Res"},{"key":"2347_CR22","first-page":"5158","volume":"39","author":"HA Uchida","year":"2022","unstructured":"Uchida HA, Nakajima H, Hashimoto M, Nakamura A, Nunoue T, Murakami K, et al. Efficacy and safety of esaxerenone in hypertensive patients with diabetic kidney disease: a multicenter, open-label, prospective study. Adv Ther. 2022;39:5158\u201375.","journal-title":"Adv Ther"},{"key":"2347_CR23","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41440-023-01292-0","volume":"46","author":"K Kario","year":"2023","unstructured":"Kario K, Nishizawa M, Kato M, Ishii H, Uchiyama K, Nagai M, et al. Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study. Hypertens Res. 2023;46:1782\u201394.","journal-title":"Hypertens Res"},{"key":"2347_CR24","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s12325-024-02780-6","volume":"41","author":"E Yamamoto","year":"2024","unstructured":"Yamamoto E, Usuku H, Sueta D, Suzuki S, Nakamura T, Matsui K, et al. Efficacy and safety of esaxerenone in hypertensive patients with left ventricular hypertrophy (ESES-LVH) study: a multicenter, open-label, prospective, interventional study. Adv Ther. 2024;41:1284\u2013303.","journal-title":"Adv Ther"},{"key":"2347_CR25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41440-023-01519-0","volume":"47","author":"T Katsuya","year":"2024","unstructured":"Katsuya T, Inobe Y, Uchiyama K, Nishikawa T, Hirano K, Kato M, et al. Exploratory study on the relationship between urinary sodium\/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study. Hypertens Res. 2024;47:835\u201348.","journal-title":"Hypertens Res"},{"key":"2347_CR26","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1007\/s12325-023-02633-8","volume":"40","author":"H Motoki","year":"2023","unstructured":"Motoki H, Inobe Y, Fukui T, Iwasaki A, Hiramitsu S, Koyama S, et al. Efficacy and safety of esaxerenone in hypertensive patients with diabetes mellitus undergoing treatment with sodium-glucose cotransporter 2 inhibitors (EAGLE-DH). Adv Ther. 2023;40:5055\u201375.","journal-title":"Adv Ther"},{"key":"2347_CR27","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/s41440-019-0270-2","volume":"42","author":"H Itoh","year":"2019","unstructured":"Itoh H, Ito S, Rakugi H, Okuda Y, Nishioka S. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. Hypertens Res. 2019;42:1572\u201381.","journal-title":"Hypertens Res"},{"key":"2347_CR28","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): Phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol. 2020;15:1715\u201327.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2347_CR29","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s10157-021-02075-y","volume":"25","author":"S Ito","year":"2021","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study. Clin Exp Nephrol. 2021;25:1070\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"2347_CR30","doi-asserted-by":"publisher","first-page":"i33","DOI":"10.1093\/ndt\/gfz264","volume":"35","author":"CCJ Dekkers","year":"2020","unstructured":"Dekkers CCJ, Gansevoort RT. Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?. Nephrol Dial Transpl. 2020;35:i33\u2013i42.","journal-title":"Nephrol Dial Transpl"},{"key":"2347_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.13854","volume":"22","author":"RJ Chilton","year":"2020","unstructured":"Chilton RJ. Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes. Diabetes Obes Metab. 2020;22:16\u201329.","journal-title":"Diabetes Obes Metab"},{"key":"2347_CR32","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1097\/HJH.0000000000003106","volume":"40","author":"Q Geng","year":"2022","unstructured":"Geng Q, Hou F, Zhang Y, Wang Z, Zhao M. Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: a meta-analysis. J Hypertens. 2022;40:996\u20131001.","journal-title":"J Hypertens"},{"key":"2347_CR33","volume":"33","author":"JL Benham","year":"2021","unstructured":"Benham JL, Booth JE, Sigal RJ, Daskalopoulou SS, Leung AA, Rabi DM. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. Int J Cardiol Heart Vasc. 2021;33:100725.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2347_CR34","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1007\/s00125-016-4017-1","volume":"59","author":"P Fioretto","year":"2016","unstructured":"Fioretto P, Stefansson BV, Johnsson E, Cain VA, Sj\u00f6str\u00f6m CD. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia. 2016;59:2036\u20139.","journal-title":"Diabetologia"},{"key":"2347_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/ehaa946.0939","volume":"41","author":"SL Kristensen","year":"2020","unstructured":"Kristensen SL, Docherty KF, Jhund PS, Bengtsson O, Demets DL, Inzucchi SE, et al. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF. Eur Heart J. 2020;41:ehaa946.0939.","journal-title":"Eur Heart J"},{"key":"2347_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","volume":"7","author":"P Rossing","year":"2021","unstructured":"Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep. 2021;7:36\u201345.","journal-title":"Kidney Int Rep"},{"key":"2347_CR37","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/jdi.13778","volume":"13","author":"K Shikata","year":"2022","unstructured":"Shikata K, Ito S, Kashihara N, Nangaku M, Wada T, Okuda Y, et al. Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter\u20092 inhibitor in patients with diabetic kidney disease: subanalysis of two phase\u2009III studies. J Diabetes Investig. 2022;13:1190\u2013202.","journal-title":"J Diabetes Investig"},{"key":"2347_CR38","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1038\/s41440-024-01818-0","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Katsuya T, Wada J, Motoki H, Kuwahara K, Tsujita K, et al. Factors influencing the efficacy and safety of esaxerenone in hypertensive patients: a pooled analysis of five clinical studies on different comorbidities. Hypertens Res. 2024;47:2826\u201339.","journal-title":"Hypertens Res"},{"key":"2347_CR39","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","volume":"143","author":"N Ye","year":"2021","unstructured":"Ye N, Jardine M, Oshima M, Hockham C, Heerspink H, Agarwal R, et al. Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease. Circulation. 2021;143:1735\u201349.","journal-title":"Circulation"},{"key":"2347_CR40","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41440-024-01762-z","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study. Hypertens Res. 2024;47:2435\u201346.","journal-title":"Hypertens Res"},{"key":"2347_CR41","doi-asserted-by":"publisher","unstructured":"Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et al. CONFIDENCE Investigators. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2410659.","DOI":"10.1056\/NEJMoa2410659"},{"key":"2347_CR42","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/ndt\/gfac157","volume":"38","author":"LM Ruilope","year":"2023","unstructured":"Ruilope LM, Pitt B, Anker SD, Rossing P, Kovesdy CP, Pecoits-Filho R, et al. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transpl. 2023;38:372\u201383.","journal-title":"Nephrol Dial Transpl"},{"key":"2347_CR43","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1007\/s12325-022-02393-x","volume":"40","author":"S Ito","year":"2023","unstructured":"Ito S, Okuda Y, Sugimoto K. Factors associated with the antihypertensive effect of esaxerenone and serum potassium elevation: a pooled analysis of seven phase III studies. Adv Ther. 2023;40:1242\u201366.","journal-title":"Adv Ther"},{"key":"2347_CR44","unstructured":"Japanese package insert of esaxerenone. 2024; ver.7 https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00070243.pdf. Accessed 15 April 2025."},{"key":"2347_CR45","doi-asserted-by":"publisher","unstructured":"Ohya Y, Sakima A. JSH2025 guidelines new viewpoints. Hypertens Res. 2025. https:\/\/doi.org\/10.1038\/s41440-025-02296-8.","DOI":"10.1038\/s41440-025-02296-8"},{"key":"2347_CR46","unstructured":"Japan Society of Nephrology. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2024. https:\/\/cdn.jsn.or.jp\/medic\/guideline\/pdf\/guide\/viewer.html?file=1-178_v2.pdf. Accessed 23 July 2023."},{"key":"2347_CR47","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","volume":"42","author":"H Rakugi","year":"2019","unstructured":"Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res. 2019;42:1932\u201341.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02347-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02347-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02347-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:02:30Z","timestamp":1762297350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02347-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2347"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02347-0","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HM has no conflicts of interest to declare. KKuwahara received research funding from Novo Nordisk Pharma Ltd. and Kowa Co., Ltd.; honoraria from MSD K.K., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AstraZeneca K.K., Astellas Pharma Inc., Novo Nordisk Pharma Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Bayer Yakuhin, Ltd., and Pfizer Japan Inc.; scholarships or donations from Otsuka Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Taisho Pharmaceutical Co., Ltd., and Fukuda Denshi Co., Ltd.; and departmental endowments from Abbott Medical Japan LLC., Medtronic Japan Co., Ltd., Biotronik Japan, Inc., Boston Scientific Japan K.K., Japan Lifeline Co., Ltd., Terumo Corporation, Nipro Corporation, and Cordis Japan G.K. HAU has no conflicts of interest to declare. JW received honoraria for speakers\u2019 bureaus from AstraZeneca K.K., and Daiichi Sankyo Co., Ltd. KKario received support for medical writing, article processing charges, research funding, and advisory fees from Daiichi Sankyo Co., Ltd.; grants from Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., Sumitomo Pharma Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd.; consulting fees from Sanwa Chemical Co., Ltd.; honoraria from Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., and Viatris Pharmaceuticals Japan G.K.; and participated in advisory boards for Novartis Pharma K.K. and Daiichi Sankyo Co., Ltd. TK received honoraria from Daiichi Sankyo Co., Ltd., CureApp, Inc., and Novartis Pharma K.K. TShimosawa had employment\/leadership position\/advisory roles with Sekisui Medical Co., Ltd., and EPS corporation; and received honoraria from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Ion Retail Co., Ltd., and Ion Happicom Co., Ltd. KT received honoraria from Abbott Medical Japan LLC., Amgen K.K., Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Kowa Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Terumo Corporation; research funding from Mochida Pharmaceutical Co., Ltd., and EA Pharma Co., Ltd.; scholarships or donations from Abbott Medical Japan LLC., ITI Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Boston Scientific Japan K.K.; and departmental endowments from Abbott Japan Co., Ltd., Boston Scientific Japan K.K., Fides-one, Inc., GM Medical Co., Ltd., ITI Co., Ltd., Kaneka Medix Co., Ltd., Nipro Corporation, Terumo Corp., Philips Japan Ltd., Getinge Group Japan K.K., Orbusneich Medical K.K., Abbott Medical Japan LLC., Biotronik Japan, Inc., Fukuda Denshi Co., Ltd., Japan Lifeline Co., Ltd., Medtronic Japan Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd. SS, T Suedomi, and TT are employees of Daiichi Sankyo Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}